Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 5/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080350 | 0.90 | ALDH1A1 (0.60) | ALDH1A1KCNH2POLBOPRM1CHRM2 | |
| SCHEMBL30626301 | 0.88 | LMNA (0.54) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL29080629 | 0.88 | LMNA (0.54) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL29080631 | 0.88 | LMNA (0.54) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5083980 | 0.85 | KDM4E (0.65) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5080567 | 0.85 | KCNH2 (0.49) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4731238 | 0.84 | KDM4E (0.53) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL10784551 | 0.82 | ALDH1A1 (0.65) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5086497 | 0.82 | KDM4E (0.47) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5084361 | 0.82 | ALDH1A1 (0.49) | LMNAALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0447484-A1 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-09-25 | — | — | EP | claimed |
| WO-1990006307-A2 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1990-06-14 | — | — | WO | claimed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-5385906-A | Treating gramnegative and grampositive bacterial infections | THE UPJOHN COMPANY (US) | 1995-01-31 | — | — | US | disclosed |
| US-5262417-A | Antibacterial quinolone compounds | THE UPJOHN COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0447484-A1 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-09-25 | — | — | EP | disclosed |
| WO-1990006307-A2 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1990-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | LMNA 415/4885ALDH1A1 2348/4885KDM4E 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.